Seattle WA T细胞淋巴瘤临床试验
6项针对 T细胞淋巴瘤的研究正在 Seattle及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
招募中2 期
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center - Montlake, Seattle
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
招募中3 期
- University of Washington Fred Hutch Cancer Center, Seattle
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
招募中3 期
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
招募中1/2 期
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
招募中1/2 期
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
招募中1 期
- Seattle Children's Hospital, Seattle
其他城市的 T细胞淋巴瘤试验
- New York City, NY12 项研究
- Baldwin Park, CA10 项研究
- Houston, TX9 项研究
- Philadelphia, PA9 项研究
- Atlanta, GA8 项研究
- Boston, MA8 项研究
- Chicago, IL6 项研究
- Columbus, OH6 项研究
- Rochester, MN6 项研究
- New Haven, CT5 项研究
- Miami, FL5 项研究
- Scottsdale, AZ4 项研究
Seattle的其他研究
- 非小细胞肺癌55 项研究
- 癌症(所有类型)48 项研究
- 前列腺癌45 项研究
- 急性髓系白血病40 项研究
- 转移性癌症39 项研究
- 乳腺癌37 项研究
- 结直肠癌35 项研究
- 肺癌34 项研究
- 卵巢癌29 项研究
- 胰腺癌22 项研究
- 多发性骨髓瘤22 项研究
- 急性淋巴细胞白血病22 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年11月15日。每项研究自行设定入选标准,由研究团队决定谁能参与。